In acquired hemophilia A (AHA), autoantibodies to coagulation factor VIII (FVIII) neutralize
FVIII activity leading to a potentially severe bleeding diathesis that carries a high rate of …

Introduction Since the approval of emicizumab, a bispecific, factor VIII‐mimetic antibody, for
use in persons with congenital haemophilia A in 2018, there have been increasing case …

Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting
autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents …

Background Emicizumab is a bispecific antibody that mimics the cofactor function of
activated factor (F) VIII. It prevents bleeds in patients with congenital hemophilia A …

Background Acquired haemophilia A is caused by neutralising autoantibodies against
coagulation factor VIII, leading to severe bleeding. Standard treatment involves …

Acquired hemophilia A (AHA) is a rare but serious bleeding disorder. Randomized
controlled trial (RCT) comparing the efficacy of immunosuppression therapy for AHA lacks …

Abstract The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the
status of AHA in Spain. One hundred and fifty-four patients were included and …

Acquired hemophilia A (AHA) is a rare severe autoimmune bleeding disorder with significant
morbidity and mortality. Although critical for disease control, there is no consensus for the …

Introduction As a typical consequence of bleeding into muscles and joints, patients with
severe hemophilia suffer from acute and chronic pain. In spite of its high prevalence, pain in …

Background Acquired haemophilia A (AHA) is a rare bleeding disorder due to
autoantibodies to coagulation factor VIII that may be secondary to autoimmune diseases …